Condition: Urothelial Carcinoma · Sponsor: Centre Francois Baclesse
The main objectif is to determine the efficacy of a maintenance treatment combining Talazoparib and Avelumab after platinum-based chemotherapy in patients with locally advanced/metastatic urothelial carcinoma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Institut de Cancérologie de l'Ouest | Angers, France | Recruiting |
| CHU Jean Minjoz | Besançon, France | Recruiting |
| Centre François baclesse | Caen, France | Active Not Recruiting |
| Centre Jean Perrin | Clermont-Ferrand, France | Recruiting |
| Centre George-François Leclerc | Dijon, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hospices civils de Lyon | Lyon, France | Active Not Recruiting |
| Institut Paoli Calmettes | Marseille, France | Not Yet Recruiting |
| Institut de Cancérologie de l'Ouest | Nantes, France | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Croix Saint-Simon Diaconesses | Paris, France | Recruiting |
| Hopital Tenon | Paris, France | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04678362